sunitinib相关论文
...
Evaluation of efficacy and safety of sunitinib regimen in 22 patients with metastatic renal cell car
...
Efficacy of sunitinib in patients with metastatic renal cell carcinoma:initial experience in two Chi
...
1例52岁男性肾透明细胞癌患者右肾切除术后1个月开始接受舒尼替尼靶向治疗(舒尼替尼50 mg口服，1次/d，连续4周，间隔2周，6周为1个周期)。......
舒尼替尼是一种靶向多种受体酪氨酸激酶(RTK)抑制剂，用于治疗晚期肾细胞癌、伊马替尼不耐受和伊马替尼耐药的难治性胃肠道间质瘤。......
狂犬病(Rabies)是由狂犬病病毒(Rabies virus,RABV)感染引起的,是一种被忽视的重要人兽共患病。经RABV感染出现临床症状后,死亡率......
目的:构建胃肠道间质瘤耐药细胞模型GIST882-Rs。方法:通过间歇浓度梯度倍增法针对胃肠道间质瘤细胞株GIST882进行体外诱导，使其对S......
研究背景及目的：肿瘤细胞对化疗药物产生原发和继发耐药是肿瘤有效治疗的主要障碍。多种机制参与肿瘤细胞耐药性的形成，包括药物作用......
目的：研究受体酪氨酸激酶抑制剂sunitinib对EGF诱导的HaCaT细胞(HaCaT/E)增殖与凋亡的影响及内在机制。方法：1.采用细胞计数的方式检......
舒尼替尼是一种口服的多靶点酪氨酸激酶抑制剂,具有抗血管生成和抑制肿瘤增殖的作用.与IFN-α相比,舒尼替尼明显提高了转移性肾癌(......
目的建立HPLC-MS/MS法同时测定人血浆中舒尼替尼及其活性代谢产物N-去乙基舒尼替尼(SU12662)的浓度。方法以氘代舒尼替尼为内标,用......
舒尼替尼对肾癌的分子靶向治疗虽然已经取得确切的临床疗效,但并非所有患者都能从中获益。单核苷酸多态性(SNP)可能是导致有些患者......
...
Multi-targeted tyrosine kinase inhibitor sunitinib: a novel strategy for sporadic malignant pheochro
Sporadic malignant pheochromocytoma,a rare disease with poor prognosis,is always difficult to treat due in part to lack ......
Evaluation of efficacy and safety of sunitinib regimen in 22 patients with metastatic renal cell car
Background Sunitinib has been proved an effective new option for treatment of metastatic renal cell carcinoma (mRCC).Ana......
Efficacy of sunitinib in patients with metastatic renal cell carcinoma:initial experience in two Chi
Background The advent of targeted therapy has proved a milestone in the history of metastatic renal cell carcinoma treat......
Sunitinib malate is one of the multitargeted tyrosine kinase inhibitor, which are being used in clinic.It can inhibit mo......
Nasal metastases from renal cell carcinoma are associated with Memorial Sloan-Kettering Cancer Cente
为探究吕家坨井田地质构造格局,根据钻孔勘探资料,采用分形理论和趋势面分析方法,研究了井田7......
Comparison of efficacy, safety, and quality of life between sorafenib and sunitinib as first-line th
为探究吕家坨井田地质构造格局,根据钻孔勘探资料,采用分形理论和趋势面分析方法,研究了井田7......
Objective To investigate the growth-inhibitory effect of sunitinib malate on human bladder transitional cell carcinoma(T......
Sunitinib effectiveness and safety as ifrst line treatment in metastatic renal cell carcinoma, in th
为探究吕家坨井田地质构造格局,根据钻孔勘探资料,采用分形理论和趋势面分析方法,研究了井田7......
【摘要】 目的 提高胃肠道间质瘤(GIST)的诊治水平。方法 分析近10年来我院收治的36名GIST患者,总结GIST的诊治结果。结果 36例均......
舒尼替尼是一个小分子多靶点酪氨酸激酶抑制剂,可抑制多个与肿瘤生长和血管生成相关的受体酪氨酸激酶.2006年被FDA批准用于不能耐......
Sunitinib malate is one of the multitargeted tyrosine kinase inhibitor, which are being used in clinic.It can inhibit mo......
目的 探讨sunitinib对血管内皮生长因子165 (VEGF165)刺激的人气道平滑肌细胞(human airway smooth muscle cells,HASMCs)合成、分......
肾细胞癌(RCC)是难治的恶性肿瘤之一,对放化疗不敏感,免疫治疗方式有效率一直徘徊于10%～15%。随着对肿瘤分子机制的深入以及多种分......
目的 观察舒尼替尼一线治疗转移性肾癌的疗效及安全性.方法 对经病理确诊的46例转移性肾透明细胞癌患者给予舒尼替尼治疗,50 mg,每......
目的 探讨舒尼替尼治疗转移性肾癌两种方案的疗效、不良反应特点及其相应处理方法.方法 舒尼替尼治疗晚期转移性肾癌病例45例,男25......
目的 探讨舒尼替尼(Sunitinib)、顺铂(CDDP)及两者联合用药对小儿睾丸卵黄囊瘤(TYST)异种移植荷瘤鼠模型的抗肿瘤作用及相关作用机......
目的 初步探讨舒尼替尼治疗转移性非透明细胞肾癌的疗效.方法 非透明细胞肾癌22例.男14例,女8例.年龄29～76岁,中位年龄46岁.根治性......
Perforation of the colon by invading recurrent gastrointestinal stromal tumors during sunitinib trea
The molecular targets of sunitinib are receptor tyrosine kinases (RTKs), and this drug has also been known to exert bloc......
目的：提高对原发性肾滑膜肉瘤的诊治水平。方法回顾性分析1例原发性肾滑膜肉瘤患者的资料，女，54岁。因左腰部疼痛6 d于2012年2月14日......
Background The tyrosine kinase inhibitors (TKIs) sunitinib, the first targeted agent for the first line treatment of met......
Multi-targeted tyrosine kinase inhibitor sunitinib: a novel strategy for sporadic malignant pheochro
Sporadic malignant pheochromocytoma,a rare disease with poor prognosis,is always difficult to treat due in part to lack ......
A series of novel derivatives of indirubin were synthesized and evaluated for their anti-proliferative activity against ......
